Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$2.55
$4.70
$2.48
▼
$179.19
$1.40M-0.0759,167 shs26,143 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.88
-5.1%		$2.33
$0.80
▼
$62.40
$870K2.21250,745 shs70,149 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
+300.0%		$0.01
$0.00
▼
$0.20
$1.31M0.746,328 shs500 shs
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-5.56%-65.12%-72.22%-97.21%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-5.08%-36.86%-69.84%-75.80%-98.43%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
+300.00%-9.09%-16.67%-83.33%-50.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$2.55
$4.70
$2.48
▼
$179.19
$1.40M-0.0759,167 shs26,143 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.88
-5.1%		$2.33
$0.80
▼
$62.40
$870K2.21250,745 shs70,149 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
+300.0%		$0.01
$0.00
▼
$0.20
$1.31M0.746,328 shs500 shs
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-5.56%-65.12%-72.22%-97.21%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-5.08%-36.86%-69.84%-75.80%-98.43%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
+300.00%-9.09%-16.67%-83.33%-50.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
1.50
ReduceN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OASM, IMCC, ARTL, and NKGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/19/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/21/2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A($17.03) per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.02N/AN/A($14.81) per share-0.06
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
OASM
Oasmia Pharmaceutical AB (publ)
$220K0.00N/AN/A$0.63 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$12.88M-$151.22N/AN/AN/AN/A-518.27%-194.29%11/17/2026 (Estimated)
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$60.66N/AN/AN/A-39.62%N/A-58.32%11/16/2026 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/AN/AN/AN/A-8,633.64%-43.94%-28.92%N/A

Latest OASM, IMCC, ARTL, and NKGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2026Q3 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$7.02N/AN/AN/AN/AN/A
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$9.92N/A$5.34 million
8/12/2026Q2 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$6.48-$0.89+$5.59-$8.01N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
3.00
3.00
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
OASM
Oasmia Pharmaceutical AB (publ)
0.11%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
OASM
Oasmia Pharmaceutical AB (publ)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
7550,000530,000Not Optionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
44990,000933,000Not Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
26130.60 million40.29 millionNot Optionable
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable

Recent News About These Companies

Double Bond Pharmaceutical International AB (DBPHAb)
October 31, 2024  |  investing.comhttps://www.investing.com/equities/double-bond-pharmaceutical-intl-income-statement
Sector-Health Care & Pharmaceuticals
May 17, 2024  |  newsweek.comN
BOEUF Bonesupport Holding AB (publ)
April 30, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/BOEUF
Resurs Holding AB (publ) (RESURS.ST)
February 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RESURS.ST/
QuiaPEG Pharmaceuticals Holding AB QUIA
January 6, 2024  |  morningstar.comM
Newbury Pharmaceuticals AB (NEWBRY)
November 29, 2023  |  investing.comhttps://www.investing.com/equities/newbury-pharmaceuticals-ab
Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme
September 26, 2023  |  bestmediainfo.comB
Lipigon Pharmaceuticals AB (LPGO)
September 14, 2023  |  investing.comhttps://www.investing.com/equities/lipigon-pharmaceuticals-ab
Speqta publ AB (SPEQT)
August 25, 2023  |  investing.comhttps://www.investing.com/equities/203-web-group-publ-ab
PRXXF Paradox Interactive AB (publ)
August 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/PRXXF
Notice of annual general meeting in Alzinova AB (publ)
April 25, 2023  |  privataaffarer.seP
Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ)
April 21, 2023  |  privataaffarer.seP
Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)
April 2, 2023  |  europapress.esE
OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M
February 26, 2023  |  seekingalpha.comhttps://seekingalpha.com/news/3940679-oxe-marine-ab-publ-non-gaap-eps-of-sek043-revenue-of-sek322m
US regulators clear way for more monkeypox vaccine shipments
July 14, 2022  |  starherald.comS
PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)
March 24, 2022  |  avanza.seA
Oasmia expands R&D ability with planned laboratory upgrade
March 17, 2022  |  privataaffarer.seP
Orexo appoints Fredrik Järrsten as new CFO
March 11, 2022  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2022/03/11/orexo-appoints-fredrik-j-xe4-rrsten-as-new-cfo
Notice of extra general meeting in Terranet AB
November 29, 2021  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2021-11/54612185-notice-of-extra-general-meeting-in-terranet-ab-399.htm
Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth | robust CAGR of 7.7% over the forecast period (2017 – 2025).
September 17, 2021  |  medgadget.comhttps://www.medgadget.com/2021/09/pet-cancer-therapeutics-market-know-how-industry-to-experience-positive-growth-robust-cagr-of-7-7-over-the-forecast-period-2017-2025.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$2.55 0.00 (0.00%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.49 -0.06 (-2.31%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$0.88 -0.05 (-5.08%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$0.86 -0.01 (-1.45%)
As of 10/23/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.01 +0.01 (+300.00%)
As of 10/23/2026 11:39 AM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas